Lumateperone

General information

Indicated for: CAPLYTA is an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults. ( 1 ) Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. ( 1 )

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 42 mg/day

Mechanism (brief)

5‑HT2A antagonism; D2 presynaptic partial agonist and postsynaptic antagonist; SERT inhibition.

Metabolism & Half‑life

• Metabolism: Multiple CYP pathways, avoid strong inhibitors/inducers per label.
• Half‑life: ~18 h.

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually

Sources

• Lumateperone label — DailyMed (2025)